Attached files
| file | filename |
|---|---|
| 10-K - 10-K - ENDOCYTE INC | ecyt-20161231x10k.htm |
| EX-32.1 - EX-32.1 - ENDOCYTE INC | ecyt-20161231ex3217fa444.htm |
| EX-31.2 - EX-31.2 - ENDOCYTE INC | ecyt-20161231ex31213ad37.htm |
| EX-31.1 - EX-31.1 - ENDOCYTE INC | ecyt-20161231ex311735e4b.htm |
| EX-23.1 - EX-23.1 - ENDOCYTE INC | ecyt-20161231ex231781f97.htm |
| EX-10.19 - EX-10.19 - ENDOCYTE INC | ecyt-20161231ex1019b76de.htm |
| EX-10.16 - EX-10.16 - ENDOCYTE INC | ecyt-20161231ex101638bfa.htm |
Exhibit 10.20
ENDOCYTE, INC.
SCHEDULE OF TERMS FOR
CHANGE IN CONTROL AND SEVERANCE AGREEMENTS
WITH EXECUTIVE OFFICERS
March 2017
|
|
|
Termination without Cause or Resignation for Good Reason, prior to a Change in Control or after 12 months following a Change in Control |
Termination without Cause or Resignation for Good Reason, within 12 months following a Change in Control |
|||||
|
Name of Executive Officer |
Date of Agreement |
Severance Payment – Percentage of Base Salary |
140% COBRA Continuation |
Accelerated vesting for equity awards that would have vested over the following |
Severance Payment – Percentage of Base Salary |
Severance Payment – Percentage of Target Bonus |
140% COBRA Continuation |
Percentage of unvested equity awards that will immediately vest |
|
Michael A. Sherman |
6/17/16 |
100% |
12 months |
12 months |
200% |
200% |
24 months |
100% |
|
Michael A. Andriole |
2/20/17 |
75% |
9 months |
9 months |
150% |
150% |
18 months |
100% |
|
Alison A. Armour |
8/10/15 |
75% |
9 months |
9 months |
150% |
150% |
18 months |
100% |
|
Beth A. Taylor |
5/15/15 |
75% |
9 months |
9 months |
100% |
100% |
12 months |
100% |
|
Michael A. Brinkley |
5/15/15 |
75% |
9 months |
9 months |
100% |
100% |
12 months |
100% |
|
Christopher P. Leamon |
5/15/15 |
75% |
9 months |
9 months |
150% |
150% |
18 months |
100% |
|
Katherine K. Parker |
5/15/15 |
75% |
9 months |
9 months |
100% |
100% |
12 months |
100% |